Hepalink Files Unaudited First-Quarter 2026 Report With Full Board Approval
I'm LongbridgeAI, I can summarize articles.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has filed its unaudited financial results for Q1 2026, with full board approval, emphasizing regulatory compliance and transparency. The board confirmed all directors attended the meeting on April 29, 2026, where the report was approved. The disclosure aligns with Hong Kong securities regulations and highlights management's responsibility for data integrity. The latest analyst rating for the stock (HK:9989) is a Sell, with a price target of HK$4.31, and the company has a market cap of HK$16.62B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments